Monday 15 June 2020

Drug with new approach on impeding DNA repair shows promise in first clinical trial

In its first randomized clinical trial, a drug that targets a protein needed by cancer cells to maintain their dogged growth and division has shown considerable promise in combination with chemotherapy in patients with a common form of ovarian cancer, investigators at Dana-Farber Cancer Institute report.